戻る
CANbridge Pharmaceuticals Inc. (01228.HK)価格
01228.HK 株価推移チャート
CANBRIDGE-B (01228.HK)
CANbridge Pharmaceuticals Inc.
HK$3.02
4.86%
$0.14
休場: Feb 16, 12:00:00 HKT
データなしEarnings FAQ
01228.HKの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
CANbridge Pharmaceuticals Inc. 01228.HKの前四半期の収益はどうでしたか？
CANbridge Pharmaceuticals Inc.の収益見積もりはいくらですか？
CANbridge Pharmaceuticals Inc.の収益品質スコアはどれくらいですか？
CANbridge Pharmaceuticals Inc.はいつ収益を報告しますか？
CANbridge Pharmaceuticals Inc.の予想収益はいくらですか？
CANbridge Pharmaceuticals Inc.は収益予想を上回りましたか？
主要データ
前終値
$2.79
始値
$2.88
当日レンジ
$2.88 - $3.3
52週レンジ
$0.114 - $3.5
取引高
10.6M
平均取引高
2.5M
1株当たり利益(TTM)
-0.36
配当利回り
--
時価総額
$1.2B
CANBRIDGE-Bとは何ですか？
CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The company is focused on research, development and commercialization of transformative therapies for rare disease. The company has a drug portfolio, with three approved drugs and a pipeline of eight assets, targeting rare disease indications that have unmet needs. These include Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria and other complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. Its pipeline includes Hunterase, Livmarli, CAN106, and CAN103. Hunterase is an enzyme replacement therapy for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. Livmarli an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter that is under development to treat rare cholestatic liver diseases including Alagille syndrome and progressive familial intrahepatic cholestasis.